Keywords: Genta, Genasense, Melanoma, Phase III
Genta’s Genasense disappoints in Ph III melanoma study
Article | 24 May 2011
USA-based Genta (OTCBB: GNTA) received a blow yesterday, when it announced that overall survival for patients treated with Genasense (oblimersen ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
